These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33230599)

  • 1. Current Landscape and Future Directions on Bladder Sparing Approaches to Muscle-Invasive Bladder Cancer.
    Broughman JR; Vuong W; Mian OY
    Curr Treat Options Oncol; 2020 Nov; 22(1):3. PubMed ID: 33230599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trimodality therapy in bladder cancer: who, what, and when?
    Premo C; Apolo AB; Agarwal PK; Citrin DE
    Urol Clin North Am; 2015 May; 42(2):169-80, vii. PubMed ID: 25882559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoradiation for organ preservation in the treatment of muscle-invasive bladder cancer.
    McHaffie DR; Kruser TJ; Gaston K; Mahoney J; Graham D; Haake M
    Urol Oncol; 2016 Jun; 34(6):271-8. PubMed ID: 27108225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions.
    Jiang DM; Chung P; Kulkarni GS; Sridhar SS
    Curr Oncol Rep; 2020 Feb; 22(2):14. PubMed ID: 32008105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
    Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bladder preservation therapy for muscle invasive bladder cancer: the past, present and future.
    Kimura T; Ishikawa H; Kojima T; Kandori S; Kawahara T; Sekino Y; Sakurai H; Nishiyama H
    Jpn J Clin Oncol; 2020 Sep; 50(10):1097-1107. PubMed ID: 32895714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy.
    El-Achkar A; Souhami L; Kassouf W
    Curr Urol Rep; 2018 Nov; 19(12):108. PubMed ID: 30392150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
    Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
    Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
    Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bladder-sparing treatment options in localized muscle-invasive bladder cancer.
    Nason GJ; Ajib K; Tan GH; Kulkarni GS
    Expert Rev Anticancer Ther; 2020 Mar; 20(3):179-188. PubMed ID: 32129122
    [No Abstract]   [Full Text] [Related]  

  • 11. Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Johnson SB; Yu JB
    Curr Oncol Rep; 2018 Jun; 20(9):66. PubMed ID: 29959582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
    J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can bladder preservation therapy come to the center stage?
    Inamoto T; Ibuki N; Komura K; Juri H; Yamamoto K; Yamamoto K; Fujita K; Nonomura N; Narumi Y; Azuma H
    Int J Urol; 2018 Feb; 25(2):134-140. PubMed ID: 29171098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Organ-sparing treatment of bladder cancer].
    Niedworok C; Shaleva A; Rübben H; Stenzl A
    Urologe A; 2016 May; 55(5):609-14. PubMed ID: 27119956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.
    Royce TJ; Feldman AS; Mossanen M; Yang JC; Shipley WU; Pandharipande PV; Efstathiou JA
    Clin Genitourin Cancer; 2019 Feb; 17(1):23-31.e3. PubMed ID: 30482661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Tri-Modality Therapy with Bladder Preservation for Selective Muscle-Invasive Bladder Cancer.
    Zhiyu Z; Qi Z; Zhen S; Jun O; Jianglei Z
    Technol Cancer Res Treat; 2021; 20():15330338211062323. PubMed ID: 34816789
    [No Abstract]   [Full Text] [Related]  

  • 17. Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Konieczkowski DJ; Efstathiou JA; Mouw KW
    Hematol Oncol Clin North Am; 2021 Jun; 35(3):567-584. PubMed ID: 33958151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trimodality therapy for bladder cancer: modern management and future directions.
    Pham A; Ballas LK
    Curr Opin Urol; 2019 May; 29(3):210-215. PubMed ID: 30855374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bladder sparing surgery in high-grade bladder cancer.
    Yakovlev PG; Klyushin DA; Vereshchako RI
    Exp Oncol; 2019 Jun; 41(2):160-165. PubMed ID: 31262149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.
    Arcangeli G; Strigari L; Arcangeli S
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):387-96. PubMed ID: 25934521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.